TIDMEKF
RNS Number : 3464Z
EKF Diagnostics Holdings PLC
20 May 2021
The following announcement from Trellus Health plc is being
linked to the EKF ticker for information purposes only
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN
PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM, THE UNITED STATES
OF AMERICA, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND OR SOUTH AFRICA
OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS
ANNOUNCEMENT. THE READER'S ATTENTION IS DRAWN TO THE DISCLAIMER AT
THE OF THIS ANNOUNCMENT.
Capitalised terms in this announcement have the same meanings as
in the Company's
RNS releases of 0700 on 18 May, 2021, unless otherwise
indicated.
Trellus Health plc
("Trellus Health" or the "Company")
Confirmation of Issue Price for Fundraising
Launch of Restricted Offer
LONDON, UK. AND NEW YORK, U.S. (20 May 2021). Trellus Health plc
(AIM: TRLS), which is commercialising a scientifically validated,
resilience-based, connected digital health solution for chronic
condition management, is pleased to announce that it is today
launching the Restricted Offer element of its Fundraising, having
received very strong levels of support for the placing and
subscription. Qualifying Shareholders are reminded that the
Restricted Offer is being made available for a limited period
only.
The Restricted Offer is being managed by the Company, with LINK
Group acting as receiving agent for applications. Further details
on the application process for the Restricted Offer can be found
below.
Key Fundraising Statistics:
Total Fundraising Size(1) : GBP28.5 million
Issue Price per Trellus Share: 40 pence
Number of Existing Trellus Shares(2) : 90,225,000
New Ordinary Shares to be issued pursuant
to the Fundraising: 71,250,000
Enlarged issued share capital on Admission 161,475,000
Market capitalisation at the Issue Price: circa GBP64.6 million
Notes:
1 Includes gross proceeds of GBP27.6 million from the placing
and subscription(3) , plus GBP0.9 million from the Restricted
Offer, in each case at the Issue Price shown above.
All 2,250,000 Ordinary Shares available under the Restricted
Offer are expected to be issued.
2 Assumes conversion of existing A shares and the single Golden
Share into Ordinary Shares shortly before Admission
3 Subscription monies raised in US$ will be converted into the
equivalent GBP sterling value of Trellus Shares at the Issue Price
(using a GBP:USD exchange rate of 1.4122, being the average of the
daily closing rates over the 5-day period to 19 May 2021, according
to FactSet)
Launch of Restricted Offer
The Company is today launching the Restricted Offer, enabling
Qualifying Shareholders only the opportunity to subscribe for New
Ordinary Shares to raise up to GBP0.9 million in gross proceeds for
the Company. The Restricted Offer is part of the total Fundraising
outlined above. Gross proceeds for the Fundraising are expected to
be GBP28.5 million in any event, as the Company has discretion to
place any Trellus Shares not applied for in the Restricted Offer
with other investors.
Qualifying Shareholders considering whether to apply for Trellus
Shares in the Restricted Offer should first read the P-Proof
Admission document in its entirety, including but not limited to
the Important Information section, Part 1 (Information on Trellus
Health plc, Market Opportunity and Growth Strategy), Part 2 (Risk
Factors), the Restricted Offer terms which will apply to any
application for Trellus Shares made under the Restricted Offer and
are set out in Part 6 (Restricted Offer Terms), and the Q&A
relating to the Restricted Offer set out in Part 7 (Restricted
Offer Q&A).
Any Qualifying Shareholder should also carefully consider if a
further investment in the Company is suitable for their investment
parameters and risk profile and are recommended to take independent
advice from their own personal financial adviser, stockbroker, bank
manager, solicitor, accountant or other independent financial
adviser authorised under the FSMA. For the avoidance of doubt
neither the directors of the Company nor N+1 Singer, the Company's
nominated adviser and corporate broker, is making any
recommendation as to what action Qualifying Shareholders should
take and the Restricted Offer is being solely organised by the
Company.
Application Process
Qualifying Shareholders wishing to apply to participate in the
Restricted Offer must complete the Application Form available
online at www.trellushealth.com/investors in accordance with the
instructions provided and return it to LINK via
restrictedoffer@trellushealth.com. Instructions for settlement of
successful applications are contained within the Application Form,
and will take place via banking direct transfers and Crest
settlement only. No cheques or bankers drafts will be accepted.
The latest time for receipt of Application Forms is 11.00 a.m.
on Monday, 24 May 2021.
Qualifying Shareholders who do not wish to take part in the
Restricted Offer should take no action.
Qualifying Shareholders with queries concerning the completion
of the Application Form should telephone the Link Group (the
"Receiving Agent") on 0371 664 0321. Calls are charged at the
standard geographic rate and will vary by provider. Calls outside
the United Kingdom will be charged at the applicable international
rate. The helpline is open between 9.00 a.m. and 5.30 p.m., Monday
to Friday excluding public holidays in England and Wales. Please
note that the Receiving Agent cannot provide any financial, legal
or tax advice and calls may be recorded and monitored for security
and training purposes.
Following the application period, the Company will announce the
result of the Restricted Offer and confirm the finalisation of the
Fundraising. The expected admission date for Trellus Shares to
commence trading on AIM is 8:00 a.m. on Friday, 28 May 2021.
Shareholders will be informed their restricted allocation just
before trading on Friday, 28 May 2021.
The Company may, in its absolute discretion, offer Trellus
Shares for which applications have not been made or accepted in the
Restricted Offer to participants in the Fundraising or such other
persons (who may not be Qualifying Shareholders) as part of the
wider Fundraising, as it deems fit.
Admission Document
An updated draft admission document, including details of the
deal size and price (the "P-Proof"), is being made available later
today to participants in the Fundraising, at
www.trellushealth.com/investors .
Please note that the P-Proof Admission Document is drafted as
though written on the intended publication date of the final form
Admission Document, and so describes certain matters that are still
in progress as though they have happened. The final Admission
Document (when published) will be made available on the Company's
website in due course, at www.trellushealth.com/investors .
Further announcements will be made as appropriate.
For further information please contact:
Trellus Health plc www.trellushealth.com.com
M onique Fayad , CEO Via Walbrook PR
Julian Baines, Chairman
As above
LINK Group (Receiving Agent)
N+1 Singer (Nominated Adviser & Broker) Tel: 020 7496 3000
Aubrey Powell / Jen Boorer / Hannah
Woodley
Walbrook PR Limited Tel: 020 7933 8780 or trellus@walbrookpr.com
Paul McManus / Sam Allen Mob: 07980 541 893 / 077502 558 258
About Trellus Health plc (www.trellushealth.com)
Trellus Health is commercialising the provision of digital
chronic condition management solutions for employers and health
plans that utilise the scientifically validated GRITT(TM)
resilience-based methodology and a proprietary HIPAA-compliant
technology platform called TrellusElevate(TM) to coordinate and
deliver personalised care remotely via telemedicine. The Company is
initially focused on Inflammatory Bowel Diseases ("IBD"), which
includes the chronic incurable conditions of Crohn's Disease and
ulcerative colitis, but considers its approach to have potential
utility and demand across many chronic conditions.
The TrellusElevate(TM) platform is the Company's proprietary
connected health platform that incorporates the GRITT(TM)
methodology and learnings on resilience from clinical research and
practice conducted at the Mount Sinai IBD Center for more than five
years. The GRITT(TM) methodology and resilience-driven
multidisciplinary care model have been scientifically validated to
demonstrate meaningful improvements in patient outcomes and over 85
per cent. reduction in unplanned healthcare utilisation (emergency
department visits and hospitalisations) which the directors of the
Company believe indicates the potential for significant cost
savings for healthcare payers.
The Company was formed in July 2020 as a UK incorporated
company, with the exclusive license for commercialisation of the
GRITT(TM) methodology for IBD and seven broad disease categories
granted by the Icahn School of Medicine at Mount Sinai ("ISMMS").
On 20 August 2020, EKF Diagnostics Holdings plc ("EKF") announced
that it had led, in partnership with ISMMS, a $5 million strategic
investment into the Company. On 18 December 2020, EKF distributed
its investment in the Company to EKF shareholders on its register
at that time, by way of a dividend in specie of its entire holding
of 27,999,999 non-voting Trellus A Shares. Transfer of these shares
took place on 18 December 2020 to Broadway Nominees Limited to be
held on trust for the underlying EKF shareholders. On Admission,
all A Shares will convert to Ordinary Shares.
Disclaimer
This announcement is an advertisement for the purposes of the
Prospectus Regulation Rules of the UK Financial Conduct Authority
("FCA") and is not a prospectus nor an admission document. This
announcement is not and does not constitute, or form part of, and
should not be construed as, an offer or invitation to sell, allot
or issue or any solicitation of any offer to purchase or subscribe
for, any securities of the Company in any jurisdiction, nor shall
it (or any part of it) or the fact of its distribution form the
basis of, or be relied upon in connection with, or act as any
inducement to enter into, any contract or commitment for securities
in the Company in any jurisdiction, including in or into the United
States, Canada, Australia, the Republic of South Africa or Japan or
their respective territories or possessions. This announcement does
not constitute a recommendation regarding any securities.
Prospective investors should not subscribe for or purchase any
securities referred to in this announcement except in compliance
with applicable securities laws and regulation and on the basis of
the information in the Pathfinder, the P-Proof of the admission
document and the final admission document ("Admission Document") to
be published by the Company, and any supplement thereto, in
connection with the Fundraising and Admission. Following
publication, a copy of the Admission Document will be made
available on the Company's website. The information in this
announcement is for background purposes only and does not purport
to be full or complete.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCPPUWPAUPGGAU
(END) Dow Jones Newswires
May 20, 2021 11:31 ET (15:31 GMT)
Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024